MEN-1703 is under clinical development by A. Menarini Industrie Farmaceutiche Riunite and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect MEN-1703’s likelihood of approval (LoA) and phase transition for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) took place on 11 Mar 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MEN-1703 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
MEN-1703 is under development for the treatment of acute myeloid leukemia (newly diagnosed), relapsed and refractory acute myeloid leukemia (AML), diffuse large B-cell lymphoma and multiple myeloma (kahler's disease) and Hodgkin lymphoma. The drug candidate is administered through oral route and formulated as capsule. It acts by targeting both PIM kinase and FLT3. It was also under development for chronic myelocytic leukemia, solid tumors, chronic lymphocytic leukemia.
A. Menarini Industrie Farmaceutiche Riunite (Menarini), formerly Farmacia Internazionale, is a biopharmaceutical company that undertakes the research, development and manufacture of several pharmaceutical products in various dosage forms. The company’s products portfolio is focused on a several therapeutic and wellness areas, including allergy, andrology, ant infective areas, cardiovascular areas, gastrointestinal disorders, gynecology and women’s wellness, respiratory areas, rheumatology, osteoporosis, dermatology and personal care, energy supplements and multivitamins, among others. Menarini operates through its manufacturing sites, and research and development centers and has a presence across Europe and Asia, Africa, and Central and South America. It distributes products across various countries worldwide through partners and distributors. Menarini is headquartered in Florence, Italy.
Quick View MEN-1703 LOA Data
|Highest Development Stage|